CBA Florida (CBAI) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014
Document And Entity Information	'
Entity Registrant Name	'Cord Blood America, Inc.
Entity Central Index Key	'0001289496
Document Type	'10-Q
Document Period End Date	30-Sep-14
Amendment Flag	'false
Current Fiscal Year End Date	'--12-31
Is Entity a Well-known Seasoned Issuer?	'No
Is Entity a Voluntary Filer?	'No
Is Entity's Reporting Status Current?	'Yes
Entity Filer Category	'Smaller Reporting Company
Entity Common Stock, Shares Outstanding	890,000,000
Document Fiscal Period Focus	'Q3
Document Fiscal Year Focus	'2014

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash	$699,433	$708,760
Accounts receivable, net of allowance for doubtful accounts of $93,123 and $81,787	323,252	155,661
Prepaid expenses	70,998	410,276
Other current assets	127,318	378,805
Total current assets	1,221,001	1,653,502
Property and equipment, net of accumulated depreciation and amortization of $621,155 and $632,851	139,026	653,772
Customer contracts and relationships, net of accumulated amortization of $3,641,671 and $3,676,947	2,035,387	3,492,899
Note receivable - Banco Vida	75,000	'
Receivable - BioCells net of discount of $215,991	489,009	'
Other Assets	'	33,957
Goodwill	'	244,053
Total assets	3,959,423	6,078,184
Current liabilities:	'	'
Accounts payable	457,524	592,844
Accrued expenses	252,878	1,114,781
Deferred revenue	1,193,340	2,245,132
Derivative Liability	338,647	359,407
Interest on promissory notes	597,050	332,155
Promissory notes payable, net of unamortized discount of $19,364 and $49,363	1,492,166	1,441,335
Total current liabilities	4,331,605	6,085,654
Deferred revenue (long term portion)	336,184	362,822
Total liabilities	4,667,789	6,448,476
Stockholders' deficit:	'	'
Preferred stock, $.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $.0001 par value, 890,000,000 shares authorized, 890,000,000 and 890,000,000 shares issued and outstanding, inclusive of treasury shares	89,000	89,000
Additional paid-in capital	53,264,971	53,264,971
Common stock held in treasury stock, 20,000 shares	-599,833	-599,833
Accumulated Other Comprehensive income	'	410,827
Accumulated deficit	-53,462,504	-53,685,436
Total Cord Blood America stockholders' deficit	-708,366	-520,470
Non-controlling interest	'	150,178
Total deficit	-708,366	-370,293
Total liabilities and stockholders' deficit	$3,959,423	$6,078,184

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Assets	'	'
Allowance for Doubtful accounts Receivables	$93,123	$81,787
Accumulated Amortization and Depreciation	621,155	632,851
Customer contracts and relationship - net of amortization	3,641,671	3,676,947
Liabilities	'	'
Promissory notes payable unamortized discount	$19,364	$49,363
Stockholders Equity	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock shares authorized	890,000,000	890,000,000
Common stock shares issued	890,000,000	890,000,000
Common stock shares outstanding	890,000,000	890,000,000
Treasury stock	20,000	20,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Condensed Consolidated Statements Of Comprehensive Income Loss	'	'	'	'
Revenue	$1,197,268	$1,487,002	$3,136,047	$4,427,223
Cost of services	-423,064	-474,862	-981,111	-1,388,947
Gross Profit	774,204	1,012,140	2,154,936	3,038,276
Administrative and selling expenses	-754,055	-1,266,149	-2,405,840	-3,543,941
Loss from operations	20,149	-253,009	-250,904	-505,665
Interest expense and change in derivative liability	518,508	-337,725	-303,159	-1,137,077
Other expenses	'	'	'	-44,227
Net loss from continuing operations before provision for income taxes	538,657	-591,734	-554,063	-1,686,969
Income taxes	'	'	'	'
Net loss from continuing operations after provision for income taxes	538,657	591,734	-554,063	-1,686,969
Gain on sale of BioCells	1,115,191	'	1,115,191	'
Loss on discontinued operations	-148,479	'	-338,196	'
Net income (loss)	1,505,370	-591,734	222,932	-1,686,969
Net income (loss) attributable to Non-Controlling Interest	'	137,901	'	279,104
Net Income (loss) attributable to Cord Blood America	1,505,370	-453,833	222,932	-1,407,865
Basic loss per share	'	'	'	'
Continuing operations	'	'	'	'
Net basic earnings per share	'	'	'	'
Diluted loss per share	'	'	'	'
Weighted average common shares outstanding	'	'	'	'
Basic weighted average common shares outstanding	890,000,000	864,218,560	890,000,000	700,137,201
Diluted weighted average common shares outstanding	890,958,445	864,974,791	890,958,445	700,893,432
Net income (loss) before income taxes	1,505,370	-591,734	222,932	-1,686,969
Foreign currency translation adjustments	'	66,856	'	141,944
Comprehensive income (loss)	1,505,370	-524,878	222,932	-1,545,025
Non-Controlling interest	'	137,901	'	279,104
Comprehensive income (loss) attributable to Cord Blood America	$1,505,370	($386,457)	$222,932	($1,265,921)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Consolidated net income (loss)	$222,932	($1,686,969)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Amortization of loan discount	50,831	387,533
Depreciation and amortization	402,252	577,804
Change in value of derivative liability	-20,760	418,321
Shares issued as payment of interest on convertible notes	'	63,866
Bad debt	943	17,090
Net change in operating assets and liabilities	'	413,455
Changes in accounts receivable	-213,003	'
Changes in other current assets	36,294	'
Changes in inventory	-18,548	'
Changes in prepaid	2,370	'
Changes in accounts payable	118,384	'
Changes in accrued expense	32,363	'
Changes in accrued interest	264,895	'
Changes in deferred revenue	77,364	'
NET CASH PROVIDED BY OPERATING ACTIVITIES OF CONTINUING OPERATIONS	956,590	333,034
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Payments for purchase of property and equipment	-38,034	-131,550
Loan to other entity	-75,000	'
NET CASH USED IN INVESTNG ACTIVITIES OF CONTINUING OPERATIONS	-113,034	-131,550
CASH FLOW USED IN DISCONTINUED OPERATION:	'	'
Net cash provided by operating activities	-630,046	'
Net cash used in investing activities	-226,422	'
Foreign currency translation from discontinued operation	3,585	201,484
NET CASH FLOW FOR THE PERIOD PROVIDED BY (USED IN) DISCONTINUED OPERATION	-852,883	201,484
NET INCREASE (DECREASE) IN CASH	-9,327	201,484
Cash balance at beginning of period	708,760	393,832
Cash balance at end of period	699,433	595,316
Supplemental Disclosures:	'	'
Interest Paid	'	'
Conversion of debt into common shares	'	782,249

1_Organization_and_Description

1. Organization and Description of Business	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 1 - Organization and Description of Business	'
	Cord Blood America, Inc. ("CBAI" or the “Company”), formerly D&A Lending, Inc., was incorporated in the State of Florida on October 12, 1999. In October, 2009, CBAI re-located its headquarters from Los Angeles, California to Las Vegas, Nevada. CBAI's wholly-owned subsidiaries include Cord Partners, Inc., CorCell Companies, Inc., CorCell, Ltd., (Cord Partners, Inc., CorCell Companies, Inc. and CorCell, Ltd. are sometimes referred to herein collectively as “Cord”), CBA Properties, Inc. ("Properties"), and Career Channel, Inc. formerly D/B/A Rainmakers International ("Rain"). In September 2010, CBAI purchased a majority interest in Biocordcell Argentina S.A. (“Bio”). CBAI and its subsidiaries engage in the following business activities:
	●	CBAI and Cord specialize in providing private cord blood and cord tissue stem cell storage services to families throughout the United States and Puerto Rico.
	●	Biocordcell Argentina S.A. specializes in providing private cord blood stem cell storage to families in Argentina, Uruguay and Paraguay.  See Note 5. Discontinued Operations
	●	Properties was formed to hold corporate trademarks and other intellectual property.
	The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that may be necessary in the event CBAI cannot continue as a going concern.

2_Summary_of_Significant_Accou

2. Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2014

Notes to Financial Statements

'

NOTE 2 - Summary of Significant Accounting Policies

'

Basis of Presentation and Going Concern

The accompanying financial statements of CBAI and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has experienced recurring net losses from operations, which losses have caused an accumulated deficit of approximately $53.46 million as of September 30, 2014. In addition, CBAI has notes and loans payable of approximately $1.49 million as of September, 2014. The Company has no available common stock outstanding as of September 30, 2014, and as such, the Company may not be able to issue common stock to retire debt until such time as the shareholders approve an increase in the number of shares authorized. These factors, among others, raise substantial doubt about CBAI's ability to continue as a going concern.

Since inception, the Company has financed cash flow requirements through the issuance of common stock and warrants for cash, services and loans. However, over the past nine quarters, the Company has reduced operating expenses, ended investment in its unconsolidated affiliates and Stellacure, and received no additional funding from outside sources for working capital. During the quarter ended September 30, 2014 the Company had positive cash flow from operations of $0.96 million. The Company plans to continue to operate on its cash flows from operations by aligning its expenses with its revenues. If cash flows from operations are significantly less than projected, then the Company would need to either cut back on its budgeted spending, look to outside sources for additional funding or a combination of the two. The Company currently does not have any financing agreements in place for additional funding. If the Company is unable to access sufficient funds when needed, obtain additional external funding or generate sufficient revenue from the sale of our products, it could be forced to curtail or possibly cease operations.

In view of these conditions, CBAI's ability to continue as a going concern is dependent upon its ability to meet its financing requirements, and to ultimately achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event CBAI cannot continue as a going concern.

Basis of Consolidation

The consolidated financial statements include the accounts of CBAI and its wholly-owned and majority-owned subsidiaries, Cord and Biocordcell Argentina S.A. All significant inter-company balances and transactions have been eliminated upon consolidation.

Deferred Revenue

Deferred revenue consists of payments for enrollment in the program and processing of umbilical cord blood and cord tissue by customers whose samples have not yet been collected, as well as the pro-rata share of annual storage fees for customers whose samples were stored during the year.

Valuation of Derivative Instruments

ASC 815-40 (formerly SFAS No. 133 "Accounting for derivative instruments and hedging activities"), requires that embedded derivative instruments be bifurcated and assessed, along with free-standing derivative instruments such as warrants, on their issuance date and in accordance with ASC 815-40-15 (formerly EITF 00-19 "Accounting for derivative financial instruments indexed to, and potentially settled in, a company's own stock") to determine whether they should be considered a derivative liability and measured at their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula. At September 30, 2014, the Company adjusted its derivative liability to its fair value, and reflected the change in fair value, in its consolidated statements of comprehensive loss.

Revenue Recognition

CBAI recognizes revenue under the provisions of ASC 605-25 (previously Staff Accounting Bulletin 104 “Revenue Recognition”). CBAI provides a combination of products and services to customers. This combination arrangement is evaluated under ASC 605-25-25 (previously Emerging Issues Task Force Issue No. 00-21, "Revenue Arrangements with Multiple Deliverables"). ASC 605-25-25 addresses certain aspects of accounting for arrangements under multiple revenue generating activities.

Cord and Bio recognize revenue from both enrollment fees and processing fees upon the completion of processing while revenue from storage fees are recognized ratably over the contractual storage period.

Franchise revenues are recognized in accordance with ASC 952-605-3, according to requirements for recognizing franchise revenues after “franchise agreement” services are completed and substantially performed. Further, in accordance with ASC 952-605-25-7, the installment or cost recovery accounting method is used to account for franchise fee revenue only in those exceptional cases when revenue is collectible over an extended period and no reasonable basis exists for estimated collectability. During the quarter ended September 30, 2014, the Company did not recognize any franchise revenues.

Impairment of Long-Lived Assets

Long-lived assets, other than goodwill, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. The Company reviews goodwill for impairment at least annually or whenever events or circumstances are more likely than not to reduce the fair value of goodwill below its carrying amount.

Equity Investments

Cord has a minority equity investment in China Stem Cells, Ltd., a Cayman Islands Company, a privately held company organized to conduct a stem cell storage business in China. In 2011, Cord acquired a minority equity investment in VidaPlus, an umbilical cord processing and storage company headquartered in Madrid, Spain. The Company utilizes the cost method of accounting as it owns less than 20% of the outstanding common stock and only has the ability to exercise nominal, not significant, influence over these companies. The cost of this investment was $204,062 and represents approximately 9.24% equity in Vidaplus. As of December 31, 2013, the Company recognized an impairment loss of $204,062 on the Vidaplus investments and notes receivable.

Fair Value Measurements

Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs, as defined by ASC 820-10, are as follows:

●

Level 1 – quoted prices in active markets for identical assets or liabilities.

●

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

●

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at September 30, 2014 of assets and liabilities measured at fair value on a recurring basis:

Level 1

Level 2

Level 3

Total

Cash and cash equivalents

$

699,433

$

—

$

—

$

699,433

Derivative liability

$

—

$

—

$

(338,647

)

$

(338,647

)

Derivative liability was valued under the Black-Scholes model, consistent with last year, with the following assumptions:

Risk free interest rate

0 to 0.13 %

Expected life

0 to 1 years

Dividend Yield

0%

Volatility

0% to 108%

The following is a reconciliation of the derivative liability:

Value at December 31, 2013

$

359,407

Change in value of derivative

$

(20,760

)

Value at September 30, 2014

$

338,647

For certain parts of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and deferred revenues, the carrying amounts approximate fair value due to their short maturities. The carrying amounts of the Company’s notes receivable and notes payable approximates fair value based on the prevailing interest rates.

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued an accounting standard update on revenue recognition that will be applied to all contracts with customers. The update requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. It also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance will be required to be applied on a retrospective basis, using one of two methodologies, and will be effective for fiscal years beginning after December 15, 2016, with early application not being permitted. The Company is currently assessing the impact that the guidance will have on the Company's financial condition and results of operations.

3_Notes_and_Loans_Payable

3. Notes and Loans Payable	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 3 - Notes and Loans Payable	'
	At September 30, 2014 and December 31, 2013 notes and loans payable consist of:
			September 30,		December 31,
			2014		2013
	Convertible Promissory Note Payable to St. George Investment, secured by the Company’s assets, interest rate of 6.0% per annum, with payment due on or before March 10, 2015		259,530		259,530
	Secured Convertible Promissory Note to Tonaquint, Inc., 6% per annum; due on or before February 27, 2014		1,252,000		1,252,000
	(See Item 1. Legal Proceedings as described more fully)
			1,511,530		1,511,530
	Less: Unamortized Discount	-19,364			(70,195	)
		$	1,492,166	$	1,441,335

4_Loans_Receivable

4. Loans Receivable	9 Months Ended
	Sep. 30, 2014
Receivables [Abstract]	'
Note 4: Loans Receivable	'
	Banco Vida
	Effective August 1, 2014, the Company entered into a secured promissory note with Banco Vida, whereby the Company provided a loan to Banco Vida in the amount of $75,000.
	The note carries an interest rate of 8% per annum.  Banco Vida is obligated to make interest-only, monthly payments for the first twelve months, commencing thirty days from the effective date, and thereafter shall repay the entirety of the principal and accrued interest pursuant to a standard 18 month amortization schedule, with the final payment being due on or before February 1, 2017. The Note is secured by Banco Vida’s customer contracts, customer relationships and the ability to collect payments directly from Banco Vida’s customers where their umbilical cord blood and tissue samples are stored at the Company’s facilities on behalf of Banco Vida.
	BioCells
	On September 29, 2014, the Company closed a transaction whereby it sold its ownership stake in BioCells, amounting to 50.004% of the outstanding shares of BioCells to Diego Rissola, who is the current President and Chairman of the Board of BioCells and a shareholder prior to the transaction.
	Under the Agreement, the Purchaser is obligated to pay the total amount of $705,000, as follows:
	$5,000 on or before October 12, 2014; $10,000 on or before December 1, 2014; $15,000 on or before March 1, 2015; $15,000 on or before June 1, 2015; $45,000 on or before June 1, 2016; $55,000 on or before June 1, 2017; $55,000 on or before June 1, 2018; $55,000 on or before June 1, 2019; $65,000 on or before June 1, 2020; $75,000 on or before June 1, 2021; $75,000 on or before June 1, 2022; $75,000 on or before June 1, 2023; $80,000 on or before June 1, 2024; $80,000 on or before June 1, 2025.
	This loan receivable is secured, non interest bearing, and subject to a 6% discount rate. As of September 30, 2014, the receivable has a balance of $489,009, net of unamortized discount of $215,991.

5_Discontinued_Operations

5. Discontinued Operations	9 Months Ended
	Sep. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Note 5. Discontinued Operations	'
	On September 29, 2014, the Company closed a transaction whereby it sold its ownership stake in BioCells, amounting to 50.004% of the outstanding shares of BioCells to Diego Rissola, who is the current President and Chairman of the Board of BioCells and a shareholder prior to the transaction.  Under the Agreement, the Purchaser is obligated to pay the total amount of $705,000.  Three payments are due by March 1, 2015, and then annually thereafter for ten years from June 1, 2015 through June 1, 2025.
	Pursuant to the Agreement, the Shares are pledged by the Purchaser in favor of the Company to secure the Purchaser’s performance under the Agreement, as are an additional 4,503 Class B shares held by the Purchaser
	In conjunction with the disposition of BioCells, the gain on the sale and results of historical operations are recorded as discontinued operations in the Company’s Consolidated Statement of Operations and reflect a gain in the amount of $1,115,191.  Additionally, the cash flows from BioCells are reflected separately as cash flows from discontinued operations in the Company’s Consolidated Statement of Cash Flows in the amount used of $852,883.
	A summary of certain assets and liabilities disposed of or discharged directly or indirectly in connection with this transaction as of September 30, 2014 was as follows:
	Cash	$	37,432
	Accounts receivable		142,510
	Other current assets		104,388
	Prepaid expenses		275,866
	Total current assets		560,196
	Property and equipment, net of accumulated depreciation		520,744
	Customer contracts and relationships, net of amortization		1,019,147
	Other assets		24,041
	Goodwill		244,053
	Total assets	$	2,368,181
	Accounts payable	$	213,054
	Accrued expenses		1,082,542
	Deferred revenue		1,192,008
	Total liabilities	$	2,487,604
	The gain on sale of BioCells reported during the period was determined as follows:
	Receivable from sale of BioCells	$	705,000
	Unamortized discount on receivable		(215,991	)
	Receivable, net of discount		489,009
	Net assets		(119,423	)
	Non-controlling interest		188,018
	Comprehensive loss		(694,777	)
	Subtotal of disposal from sale of BioCells		(626,182	)
	Net gain on sale of BioCells	$	1,115,191

6_Commitments_and_Contingencie

6. Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 6 - Commitments and Contingencies	'
	St. George Investments
	On March 10, 2011, the Company entered into a Note and Warrant Purchase Agreement (the "Purchase Agreement") with St. George Investments, LLC, (“St. George”) an Illinois limited liability company (the "Investor") whereby the Company issued and sold, and the Investor purchased: (i) Secured Convertible Promissory Notes of the Company in the principal amount of $1,105,500 (the "Company Note") and (ii) a Warrant to purchase common stock of the Company (the "Warrant"). The Investor paid $250,000 in cash as an initial payment to the Company and executed and delivered six separate “Secured Buyer Notes” (the “Buyer Notes”), as consideration in full for the issuance and sale of the Company Note and Warrants.
	The principal amount of the Company Note is $1,105,500 ("Maturity Amount") and the Company Note is due 48 months from the issuance date of March 10, 2011. The Company Note has an interest rate of 6.0%, which would increase to a rate of 12.0% on the happening of certain Trigger Events, including but not limited to: a decline in the 10-day trailing average daily dollar volume of the common shares in the Company’s primary market to less than $30,000 of volume per day at any time; the failure by the Company or its transfer agent to deliver Conversion Shares (defined in the Company Note) within 5 days of Company’s receipt of a Conversion Notice (defined in the Company Note). Due to a triggering event occurring, the current interest rate is 12%. The total amount funded (in cash and notes) was $1,000,000, representing the Maturity Amount less an original issue discount of $100,500 and the payment of $5,000 to the Investor to cover its fees, with payment consisting of $250,000 advanced at closing and $750,000 in a series of six secured convertible Buyer Notes of $125,000 each, with interest rates of 5.0%. To date, St. George has paid the total amount due.
	The Buyer Notes are secured by an Irrevocable Standby Letter of Credit (“Letter of Credit”). The warrant also contains a net exercise /cashless exercise provision. St. George may elect to convert all or part of the principal and any accrued unpaid interest on the Company Note on or before the aforementioned maturity date, subject to certain limitations. The conversion price under the Company Note is eighty percent (80%) of the average of the closing bid prices for the three (3) Trading Days (defined in the Purchase Agreement) with the lowest closing bids over the twenty (20) Trading Days immediately preceding the Conversion Date (defined in the Company Note), subject to adjustments as set forth in the Company Note. Due to adjustments, St. George’s current conversion ratio inserts fifty-five percent (55%) in the aforementioned formula, in place of eighty percent (80%).
	The Investor has also received a five year warrant entitling it to purchase shares of common stock of the Company at an exercise price determined under the terms of the Warrant. The warrant also contains a net exercise /cashless exercise provision.
	As of September 30, 2014 the balance due to St. George Investments was $259,530 in principal and $43,279 in accrued interest.
	The Company Note, Warrant and related documentation, including any amounts owed by the Company to St. George based thereon, are in dispute and are the subject of litigation, as described more fully in Item 1. Legal Proceedings.
	Tonaquint, Inc.
	In a transaction that closed on June 29, 2012, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with Tonaquint, Inc. (“Tonaquint”) a Utah corporation whereby the Company issued and sold, and Tonaquint purchased a Secured Convertible Promissory Note of the Company in the principal amount of $1,252,000 (the "Company Note").
	The Company Note was issued June 27, 2012 and is due 20 calendar months after the issuance date. The Company Note has an interest rate of 6.0%, which would increase to a rate of 18.0% on the happening of certain Events of Default (defined in the Company Note), including but not limited to: failure to pay and the failure by the Company or its transfer agent to deliver Conversion Shares (defined in the Company Note) within 3 Trading Days of the Company’s receipt of a Conversion Notice (defined in the Company Note). Tonaquint has claimed an interest rate of 18%, which is being disputed by the Company. The total amount funded in cash at closing was $1,120,000, representing the principal amount less an original issue discount of $112,000 and the payment of $20,000 to Tonaquint to cover its fees.
	Tonaquint has the right to convert, subject to restrictions described in the Company Note, all or a portion of the outstanding amount of the Company Note into shares of the Company’s common stock at a price of $0.03. So long as Tonaquint has not extinguished the Company Note in its entirety pursuant to such conversions, the Company shall make monthly payments to Tonaquint on the Company Note, through either the issuance of shares of the Company’s common stock or by payment in cash, at the election of the Company. Payments commence six months from the date of issuance of the Company Note and continue until the Company Note has been paid in full. The amount of the monthly payments is the greater of (i) $100,000, plus the sum of any accrued and unpaid interest as of the applicable Installment Date (defined in the Company Note) and accrued and unpaid Late Charges (defined in the Company Note), if any, under the Company Note as of the applicable Installment Date (defined in the Company Note), and any other amounts accruing or owing to Investor under the Company Note as of such Installment Date, or (ii) the then-outstanding balance of the Company Note divided by the number of Installment Dates remaining prior to the Maturity Date.
	In the event the Company is unable to make payments in cash or otherwise elects not to make a payment or payments in cash, the number of common shares delivered to the Investor upon conversion will be calculated by dividing the amount of the Company Note that is being converted by the market price of the common stock, which is defined as 80% of the arithmetic average of the three (3) lowest volume weighted average prices of the shares of the Company’s common stock during the twenty three (23) consecutive trading day period immediately preceding the date as of which such price determination is required (such as the effective date of a conversion).
	As of September 30, 2014, the amount owed to Tonaquint was $1,252,000 of principal and $553,771 in accrued interest in accordance with Tonaquint’s claim which is being disputed by the Company.
	The Company Note, Purchase Agreement and other related documents, including any amounts owed by the Company to Tonaquint based thereon, are in dispute and are the subject of litigation, as described more fully in Item 1. Legal Proceedings.
	VidaPlus
	On January 24, 2011, the Company entered into a Stock Purchase Agreement to acquire up to 51% of the capital stock in VidaPlus, an umbilical cord processing and storage company headquartered in Madrid, Spain. The Agreement is organized into three tranches; the first executed at closing with an initial investment of approximately $204,000 (150,000 Euro) for an amount equivalent to 7% as follows; 1% of share capital in initial equity or approximately $30,000 and 6% or an estimated $174,000 as a loan convertible into equity within 12 months of closing. The initial investment was secured by a Pledge Agreement on 270 VidaPlus samples that are incurring annual storage fees. The second tranche provides the opportunity for an additional 28% in share capital through monthly investments based on the number of samples processed in that month (up to a maximum of 550,000 EUR). In connection with Tranche 2, the Company has loaned VidaPlus $246,525 to date. Converting the investment from a loan into equity will take place within 24 months of the date the amount of shares due to the Company pursuant to the second tranche is calculated. The third tranche follows a similar loan to equity agreement as tranche two but for an additional 16% equity at the option of the Company (up to a maximum of 550,000 EUR). VidaPlus contracts through Stellacure and their relationship with the German Red Cross for their processing and storage.
	In connection with the VidaPlus Stock Purchase Agreement entered into on January 24, 2011, the Company is obligated to make monthly loans to VidaPlus based on the number of new samples processed and up to a maximum of 550,000 Euro for each of Tranche 2 and 3 of the Agreement. Tranche 2 did contain provisions that provided the Company an option to discontinue funding if certain performance targets were not met.
	In January 2012, the Company exercised its right to convert its Tranche 1 loan into 6% of the outstanding shares of VidaPlus, and as a result, the Company owned a total of 7% of the outstanding shares. At the time of the equity conversion, the Company no longer maintained its Pledge on the 270 VidaPlus samples associated with Tranche 1; however, the Company maintained a liquidation preference in VidaPlus over the money invested by the Company in VidaPlus. Additionally, the Company declined to make any further investment (loan or otherwise) to VidaPlus under whether Tranche 2, Tranche 3 or otherwise. CBAI holds a pledge over the umbilical cord blood maintenance and storage contracts between VidaPlus and certain of its customers, and all rights contained therein, including but not limited to the rights to administer those contracts and the rights to collect the revenues derived from those contracts, for 328 samples. CBAI holds that pledge until such time as it converts the monies paid to VidaPlus under Tranche 2 of the Stock Purchase Agreement into equity into Vidaplus, in accordance with the formulas set forth in the Stock Purchase Agreement. CBAI must make that conversion within two years of when the calculation was made as to the amount of shares to which CBAI is entitled pursuant to Tranche 2, which means that such conversion shall take place around or before February 2014. CBAI also holds a liquidation preference in VidaPlus for the money the Company invested in VidaPlus. On February 14, 2014, CBAI delivered to VidaPlus its election to convert its loan under Tranche 2 into shares of stock in VidaPlus, including Anti-Dilution shares.  The Company is entitled to an additional ownership stake of approximately 2.24% in connection with the forgoing, bringing its total ownership percentage to approximately 9.24%
	Patent License Agreement
	PharmaStem Therapeutics claims to hold certain patents relating to the storage, expansion and use of hematopoietic stem cells. In the past several years, PharmaStem has commenced suit against numerous companies involved in cord blood collection and preservation alleging infringement of its patents. In October 2003, after a jury trial, judgment was entered against certain of our competitors and in favor of PharmaStem in one of those suits. In February 2004, PharmaStem commenced suit against Cord Partners and certain of its competitors alleging infringement of its patents. Management of Cord Partners determined to settle, rather than to litigate, this matter. As a result, PharmaStem and Cord Partners entered into a Patent License Agreement in March 2004. Pursuant to the Patent License Agreement, Cord Partners could, on a non-exclusive basis, collect, process and store cord blood utilizing PharmaStem’s claimed technology and processes allegedly covered by its patents for so long as the patents may remain in effect. Most of the patents at issue expired in 2010. PharmaStem could claim, arguendo, Cord Partners is obligated under the Patent License Agreement to pay royalties to PharmaStem of 15% of all revenues generated by Cord Partners from the collection and storage of cord blood on and after January 1, 2004. Other than, potentially royalties, which would be disputed by Cord, no amount is payable by Cord Partners to PharmaStem. All litigation between the parties was dismissed and all prior claims were released. As of 2008, Cord ceased paying all royalties to PharmaStem. The patents have been declared void under a final decision on appeal, and as such, there is no pending litigation in this matter. As of September 30, 2014, the Company included approximately $226,000 in accounts payable and $120,000 included in accrued expenses to account for this liability since 2008, though the Company disputes that it owes any royalties to Pharmastem.
	Commitments and Contingencies
	Employment Agreements
	On September 12, 2011 (the “Company”), entered into an Executive Employment Agreement with Joseph R. Vicente, then the Company’s Chief Operating Officer and Vice President and appointed Chairman and President on May 15, 2012 by the Board of Directors, which was effective as of August 1, 2011 and shall terminate as of December 31, 2014, unless earlier terminated by the Company or Mr. Vicente. Mr. Vicente’s Executive Employment Contract had an initial term from August 1, 2011 through December 31, 2011, and is renewable annually thereafter for up to three additional, successive years, and provides for a base salary equal to his previous year’s annual salary, which said salary was set under the provisions of the previous employment agreement entered between Mr. Vicente and the Company in July of 2008. Mr. Vicente voluntarily reduced his annual salary by 12.5% until otherwise determined by Mr. Vicente, along with the advice and consent of the Company’s Board of Directors. It also provides for an annual bonus, payable at the discretion of the Board of Directors, equal to 25% of Mr. Vicente’s prior year base salary. The Agreement provides for a change of control termination bonus, which provide that if Mr. Vicente is terminated, his compensation reduced, or Mr. Vicente terminates his employment within one year after a change of control, then Mr. Vicente is entitled to a termination benefit in an amount equal to the average annual cash compensation over the three (3) year period preceding the Triggering Event (defined in the agreements) multiplied (2.00). The Agreement also provides for termination payments in the absence of a change of control in the event the Company terminates Mr. Vicente without cause in an amount equal to all compensation paid by the Company to Mr. Vicente for the 24 months preceding the termination, along with health plan and 401k incentives (if any were to be offered – the Company terminated its 401k earlier in 2012), as stated in the agreement.
	The Company entered into an Executive Employment Agreement with Stephen Morgan (the “Employee”) on August 10, 2012, with July 1, 2012 as the effective date of the Agreement. The Agreement provides for a change of control termination bonus, whereby if the Employee is terminated, his compensation reduced, or the Company terminates the Employee’s employment within one year after a change in control, then the Employee is entitled to a termination benefit in an amount equal to the employee’s cash compensation over the one (1) year preceding the Triggering Event (defined in the Agreement). The Agreement also provides for termination payments in the absence of a change of control in the event the Company terminates the Employee without cause in an amount equal to all compensation paid by the Company to the Employee for the 12 months preceding the termination, along with health plan and 401k incentives (if any were to be offered – the Company terminated its 401k earlier in 2012), as stated in the Agreement. The Agreement provides for an annual salary of $125,000, along with a bonus, payable at the discretion of the Board of Directors of up to an annual amount of 20% of the Employee’s salary. Mr. Morgan’s compensation, as set forth in the Agreement has not increased as a result of his election to the officer positions of Vice President and Secretary on May 15, 2012 in addition to his retention of his previous position, General Counsel. The Company believes the assumption of additional roles by existing management and other individuals in leadership positions, including filling recently vacated roles, will reduce overall management costs while also leading to greater efficiency within the organization.
	Operating Leases
	On January 21, 2014, the Company entered a First Amendment to Lease, which extended its lease at the property located at 1857 Helm Drive, Las Vegas, Nevada through September 30, 2019.  In connection with the amendment, the Company received an abatement of the entire amount of its rent for January 2014, except for CAM charges.  In addition, as of October 1, 2014, the Company’s monthly lease payments shall revert back to their rates as they existed in June 2009, other than CAM charges, with annual adjustments thereafter as set forth in the Amendment.  Moreover, the Landlord has the option to lease a portion of the premises currently occupied by the Company to a third party, and if this portion is leased to a third party, the Company’s monthly rent amount shall be reduced pro rata with the portion of the space leased to a third party.  If the Landlord is unable to or elects not to lease a portion of the premises to a third party by November 30, 2015 and by each subsequent anniversary thereof, the Company shall receive an additional abatement of one month rent, excluding CAM charges, in December 2015, December 2016 and December 2017, respectively and as applicable.
	Commitments for future minimum rental payments, by year, and in the aggregate, to be paid under such operating lease as of September 30, 2014, are as follows:
		Rent
		to be paid
	2014	$	43,839
	2015		176,497
	2016		180,997
	2017		185,354
	2018		189,842
	Thereafter		144,962
	Total	$	921,490

7_Related_Party_Transactions_a

7. Related Party Transactions and Commitments	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 7 - Related Party Transactions and Commitments	'
	China Stem Cells, Ltd.
	In March of 2010 the Company acquired pursuant to a License Agreement, a 10% non dilutable interest in what became, in December 2010, China Stem Cells, Ltd., a Cayman Islands Company (hereinafter "Cayman"), which indirectly holds a 100% capital interest in AXM Shenyang, a company organized to conduct a Stem Cell Storage Business in China. In exchange for issuance of an equity interest in Cayman, under the terms of the Transfer of Technology Agreement the Company agreed to provide technology transfer, knowhow and training in the setup, marketing and operation of the China Stem Cell Storage business. In connection with the License Agreement, the Company is to receive royalties equal to 8.5% of "Net Revenues" realized from the China Stem Cell Storage business, over the 15 year term of the agreement, with certain minimum annual royalties’ payable beginning in 2011. The Company has not been paid any royalty balance due to date, and it remains doubtful that any such royalties will be collected.
	In December of 2010 the Company also acquired the option to provide up to $750,000 of additional capital funding to Cayman through the purchase of Cayman Secured Convertible Promissory Notes and attached Cayman Warrants to acquire its Common Stock. Other Cayman shareholders were granted similar options, with the intent of raising the aggregate up to $1.5 million in additional capital for Cayman and its subsidiaries. CBAI has exercised this option in part, provided a total of $400,000 in additional capital to Cayman, and is to receive Cayman Secured Convertible Promissory Notes for this sum along with 80 Cayman (TBD) Warrants. The Secured Convertible Promissory Notes are convertible into Cayman stock at a conversion price of $1,500 per share, subject to certain adjustments. The Warrants have a five year term and are exercisable at an option exercise price of $0.05 per share per share, subject to certain adjustments. The Company has recorded a reserve for the entire carrying amount of the receivable, including interest. The Company’s current President, Joseph Vicente was appointed as a Director of China Stem Cells Ltd. in July 2012.
	VidaPlus
	The Company holds approximately 9.24% of the outstanding shares of VidaPlus, and has a balance of convertible loans receivable amounting to $246,525. During the year ended December 31, 2012, the Company reviewed the recoverability of the equity investment and loans receivable and the carrying amount exceeds the fair value of the investment as a result of recurring and continued operating losses at VidaPlus. Fair value of the loans receivable is determined based on the discounted future net cash flows expected to be generated by assets pledged against the loans. The Company recorded an impairment of 100% of the book value of the equity investment and convertible loan receivable.
	Frozen Food Gift Group, Inc.
	CBAI engaged Frozen Food Gift Group, Inc. (“FFGG”) as a vendor, prepaying for $45,000 in products during the year ended December 31, 2011. The remaining balance on that account was $30,655 as of March 31, 2013, not including additional interest and fees to which the Company may be entitled. The Company’s former CEO and Chairman of the Board, Mathew Schissler who resigned effective May 14, 2012, owned 36.2% of the outstanding shares of FFGG based on an S-1 filing made by that company with the SEC on July 31, 2012, and on information and belief is FFGG’s Chairman of the Board.  CBAI’s former COO, and now President Joseph Vicente served on the Board of Directors of FFGG, but resigned effective as of January 26, 2012.
	The Company entered into a Release with FFGG effective as of March 5, 2014, with the mutual releases and negative covenants contained therein not taking effect until such time as the Company received payment under the Claim Purchase Agreement, entered as of March 12, 2014 with a third party to the Company in exchange for the Company’s claims against FFGG.  Payment was made by a third party to the Company on or around April 1, 2014.

8_Share_Based_Compensation

8. Share Based Compensation	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 8 - Share Based Compensation	'
	Stock Option Plan
	The Company's Stock Option Plan permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 8.0 million shares of its common stock. The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company. On July 13, 2009, the Company registered its 2009 Flexible Stock Plan, which increases the total shares available to 4 million common shares. The agreement allows the Company to issue either stock options or common shares from this Plan.
	On June 3, 2011, the Company registered its 2011 Flexible Stock Option plan, and reserved 1,000,000 shares of the Company's common stock for future issuance under the Plan. The Company canceled the Company's 2010 Flexible Stock Plan, and returned 501,991 reserved but unused common shares back to its treasury.
	Stock options that vest at the end of a one-year period are amortized over the vesting period using the straight-line method. For stock options awarded using graded vesting, the expense is recorded at the beginning of each year in which a percentage of the options vests. The Company did not issue any stock options for the period ended September 30, 2014.
	The Company’s stock option activity was as follows:
			Stock				Weighted Average Exercise Price				Weighted Avg. Contractual
			Options								Remaining Life
	Outstanding, January 1, 2013			6,323,570				1.01				5.76
	Exercised			-				-				-
	Forfeited/Expired			627,740				-				-
	Outstanding, December 31, 2013			5,570,830				1.01				4.51
	Exercisable at December 31, 2013			5,570,830				1.01				4.51
	Forfeited/Expired			12,000				-				-
	Outstanding, June 30, 2014			5,558,830				1.01				4.01
	Exercisable at June 30, 2014			5,558,830				1.01
	Forfeited/Expired			462,055
	Outstanding, September 30, 2014			5,106,775				1.01				3.51
	Exercisable, September 30, 2014			5,106,775				1.01
	The following table summarizes significant ranges of outstanding stock options under the stock option plan at September 30, 2014:
	Range of				Number of				Weighted Average				Weighted Average		Number of		Weighted Average
	Exercise Prices				Options				Remaining				Exercise		Options		Exercise
									Contractual Life				Price		Exercisable		Price
									(years)
	$	0.33 — 20.00				5,070,751				3.53			$	0.83		5,070,751	$	0.72
	$	21.00 — 30.00				18,126				0.37				25		18,126		15.04
	$	31.00— 51.00				17,898				3.51				31.21		17,898		31.21
						5,106,775				3.51			$	1.01		5,106,775	$	1.01
	A summary of the activity for unvested employee stock options as of September 30, 2014 and changes during the period presented below:
	Weighted Average Grant Date Fair Value per Share
			Stock				Weighted Avg.
			Options				Grant Date
							Fair Value per
							Share
	Nonvested at January 1, 2014			--				0.39
	Granted			--				--
	Vested			--				--
	Exercised			--				--
	Cancelled			--				--
	Pre-vested forfeitures			--				--
	Nonvested at September 30, 2014			--				0.39
	The total compensation cost related to non-vested options amounts to $0. All outstanding unexercised options provide for adjustment upon stock split, as well as under certain other circumstances.

9_Warrant_Agreements

9. Warrant Agreements	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 9 - Warrant Agreements	'
	On March 10, 2011 the Company issued a Promissory Note for $1,105,000 to St. George Investments along with 1,392,354 five year warrants at $0.01 per share.
	The Company has not issued any warrants since January 1, 2012.
	The following table summarizes the warrants outstanding and exercisable at September 30, 2014:
		WARRANTS OUTSTANDING		EXERCISE		MATURITY DATE
				PRICE
			1,392,354	$	0.01	3/10/16
	Total		1,392,354

10_Stockholders_Equity

10. Stockholder's Equity	9 Months Ended
	Sep. 30, 2014
Stockholders Equity	'
10. Stockholder's Equity	'
	Preferred Stock
	CBAI has 5,000,000 shares of $.0001 par value preferred stock authorized.
	Common Stock
	On September 25, 2012, the Company’s Articles of Incorporation were amended to increase the authorized common stock to 890,000,000 shares, par value $0.0001, up from 250,000,000. This amendment was adopted by the Company’s Board of Directors on July 11, 2012, and its Shareholders at a Special Meeting of Shareholders called for this purpose on September 25, 2012.
	During the year ended December 31, 2013, the Company issued 513,765,592 shares of common stock to retire $776,502 of principal and interest in convertible debt which had a fair market value of $1,823,206.
	As of September 30, 2014; CBAI had 890,000,000 shares of Common Stock outstanding. 20,000 shares remain in the Company's treasury.

11_Segment_Reporting

11. Segment Reporting	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 11 - Segment Reporting	'
	Guidance issued by the FASB requires that public business enterprises report financial and descriptive information about its reportable operating segments. Cord primarily generates revenues related to the processing and storage of umbilical cord blood and cord tissue. Cord’s long-lived assets are located in, and substantially all of its revenues are generated from, the United States of America and Argentina.
	The table below presents certain financial information by business segment for the nine months ended September 30, 2014:
		Cord		Biocordcell		Segment		Consolidation		Condensed
						Total		Eliminations		Consolidated
										Total
	Revenue fromExternal Customers	$	3,136,047	$	--	$	3,136,047	$	-	$	3,136,047
	Interest & Derivative Expense		303,159		--		303,159		-		303,159
	Depreciation and Amortization		402,252		--		402,252				402,252
	Segment Loss from continuing operations		-554,063		--		-554,063		-		-554,063
	Gain from discontinued operations				776,995		776,995				776,995
	Segment Assets	$	3,959,423	$	--	$		$	3,959,423	$	3,959,423
	The table below presents certain financial information by business segment for the three months ended September 30, 2014:
		Cord		Biocordcell		Segment		Consolidation		Condensed
						Total		Eliminations		Consolidated
										Total
	Revenue from External Customers	$	1,197,268	$	--	$	1,197,268	$	-	$	1,197,268
	Interest & Derivative Expense		518,508		--		518,508				518,508
	Depreciation and Amortization		133,692		--		133,692				133,692
	Segment Income from continuing operations		538,657		--		538,657		-		538,657
	Gain from discontinued operations				966,712		966,712				966,712
	Segment Assets	$	3,959,423	$	--	$	3,959,423	$		$	3,959,423
	The table below presents certain financial information by business segment for the nine months ended September 30, 2013:
		Cord		Biocordcell		Segment		Consolidation		Condensed
						Total		Eliminations		Consolidated
										Total
	Revenue from External Customers	$	2,842,703		1,584,520		4,427,223				4,427,223
	Interest & Derivative Expense		1,045,512		91,565		1,137,077				1,137,077
	Depreciation and Amortization		540,630		37,174		577,804				577,804
	Segment Loss from continuing operations		-1,128,761		-558,208		-1,686,969				(1,686,969	)
	Segment Assets	$	4,655,965		1,892,027		6,547,992		-138,383		6,409,609
	The table below presents certain financial information by business segment for the three months ended September 30, 2013:
		Cord		Biocordcell		Segment		Consolidation		Condensed
						Total		Eliminations		Consolidated
										Total
	Revenue from External Customers	$	959,239		527,763		1,487,002				1,487,002
	Interest & Derivative Expense		289,824		47,901		337,725				337,725
	Depreciation and Amortization		180,024		11,976		192,000				192,000
	Segment Loss from continuing operations		-315,932		-275,802		-591,734				-591,734
	Segment Assets	$	4,655,965		1,892,027		6,547,992		-138,383		6,409,609

12_Subsequent_Events

12. Subsequent Events	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
NOTE 10 - Subsequent Events	'
	The Company’s Management has reviewed all material events through the date of this report in accordance with ASC 855-10, and believes there is no subsequent events of which should have any material effect on financial statements.

2_Summary_of_Significant_Accou1

2. Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2014

Summary Of Significant Accounting Policies Policies

'

Basis of Presentation and Going Concern

'

The accompanying financial statements of CBAI and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has experienced recurring net losses from operations, which losses have caused an accumulated deficit of approximately $53.46 million as of September 30, 2014. In addition, CBAI has notes and loans payable of approximately $1.49 million as of September, 2014. The Company has no available common stock outstanding as of September 30, 2014, and as such, the Company may not be able to issue common stock to retire debt until such time as the shareholders approve an increase in the number of shares authorized. These factors, among others, raise substantial doubt about CBAI's ability to continue as a going concern.

Since inception, the Company has financed cash flow requirements through the issuance of common stock and warrants for cash, services and loans. However, over the past nine quarters, the Company has reduced operating expenses, ended investment in its unconsolidated affiliates and Stellacure, and received no additional funding from outside sources for working capital. During the quarter ended September 30, 2014 the Company had positive cash flow from operations of $0.96 million. The Company plans to continue to operate on its cash flows from operations by aligning its expenses with its revenues. If cash flows from operations are significantly less than projected, then the Company would need to either cut back on its budgeted spending, look to outside sources for additional funding or a combination of the two. The Company currently does not have any financing agreements in place for additional funding. If the Company is unable to access sufficient funds when needed, obtain additional external funding or generate sufficient revenue from the sale of our products, it could be forced to curtail or possibly cease operations.

In view of these conditions, CBAI's ability to continue as a going concern is dependent upon its ability to meet its financing requirements, and to ultimately achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event CBAI cannot continue as a going concern.

Basis of Consolidation

'

The consolidated financial statements include the accounts of CBAI and its wholly-owned and majority-owned subsidiaries, Cord and Biocordcell Argentina S.A. All significant inter-company balances and transactions have been eliminated upon consolidation.

Deferred Revenue

'

Deferred revenue consists of payments for enrollment in the program and processing of umbilical cord blood and cord tissue by customers whose samples have not yet been collected, as well as the pro-rata share of annual storage fees for customers whose samples were stored during the year.

Valuation of Derivative Instruments

'

ASC 815-40 (formerly SFAS No. 133 "Accounting for derivative instruments and hedging activities"), requires that embedded derivative instruments be bifurcated and assessed, along with free-standing derivative instruments such as warrants, on their issuance date and in accordance with ASC 815-40-15 (formerly EITF 00-19 "Accounting for derivative financial instruments indexed to, and potentially settled in, a company's own stock") to determine whether they should be considered a derivative liability and measured at their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula. At September 30, 2014, the Company adjusted its derivative liability to its fair value, and reflected the change in fair value, in its consolidated statements of comprehensive loss.

Revenue Recognition

'

CBAI recognizes revenue under the provisions of ASC 605-25 (previously Staff Accounting Bulletin 104 “Revenue Recognition”). CBAI provides a combination of products and services to customers. This combination arrangement is evaluated under ASC 605-25-25 (previously Emerging Issues Task Force Issue No. 00-21, "Revenue Arrangements with Multiple Deliverables"). ASC 605-25-25 addresses certain aspects of accounting for arrangements under multiple revenue generating activities.

Cord and Bio recognize revenue from both enrollment fees and processing fees upon the completion of processing while revenue from storage fees are recognized ratably over the contractual storage period.

Franchise revenues are recognized in accordance with ASC 952-605-3, according to requirements for recognizing franchise revenues after “franchise agreement” services are completed and substantially performed. Further, in accordance with ASC 952-605-25-7, the installment or cost recovery accounting method is used to account for franchise fee revenue only in those exceptional cases when revenue is collectible over an extended period and no reasonable basis exists for estimated collectability. During the quarter ended September 30, 2014, the Company did not recognize any franchise revenues.

Impairment of Long-Lived Assets

'

Long-lived assets, other than goodwill, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. The Company reviews goodwill for impairment at least annually or whenever events or circumstances are more likely than not to reduce the fair value of goodwill below its carrying amount.

Equity Investments

'

Cord has a minority equity investment in China Stem Cells, Ltd., a Cayman Islands Company, a privately held company organized to conduct a stem cell storage business in China. In 2011, Cord acquired a minority equity investment in VidaPlus, an umbilical cord processing and storage company headquartered in Madrid, Spain. The Company utilizes the cost method of accounting as it owns less than 20% of the outstanding common stock and only has the ability to exercise nominal, not significant, influence over these companies. The cost of this investment was $204,062 and represents approximately 9.24% equity in Vidaplus. As of December 31, 2013, the Company recognized an impairment loss of $204,062 on the Vidaplus investments and notes receivable.

Fair Value Measurements

'

Fair Value Measurements

Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs, as defined by ASC 820-10, are as follows:

●

Level 1 – quoted prices in active markets for identical assets or liabilities.

●

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

●

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at September 30, 2014 of assets and liabilities measured at fair value on a recurring basis:

Level 1

Level 2

Level 3

Total

Cash and cash equivalents

$

699,433

$

—

$

—

$

699,433

Derivative liability

$

—

$

—

$

(338,647

)

$

(338,647

)

Derivative liability was valued under the Black-Scholes model, consistent with last year, with the following assumptions:

Risk free interest rate

0 to 0.13 %

Expected life

0 to 1 years

Dividend Yield

0%

Volatility

0% to 108%

The following is a reconciliation of the derivative liability:

Value at December 31, 2013

$

359,407

Change in value of derivative

$

(20,760

)

Value at September 30, 2014

$

338,647

For certain parts of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and deferred revenues, the carrying amounts approximate fair value due to their short maturities. The carrying amounts of the Company’s notes receivable and notes payable approximates fair value based on the prevailing interest rates.

Recently Issued Accounting Pronouncements

'

In May 2014, the FASB issued an accounting standard update on revenue recognition that will be applied to all contracts with customers. The update requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. It also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance will be required to be applied on a retrospective basis, using one of two methodologies, and will be effective for fiscal years beginning after December 15, 2016, with early application not being permitted. The Company is currently assessing the impact that the guidance will have on the Company's financial condition and results of operations.

2_Summary_of_Significant_Accou2

2. Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2014
Summary Of Significant Accounting Policies Tables	'
Fair value measurements for assets and liabilities	'
		Level 1			Level 2		Level 3			Total
	Cash and cash equivalents	$	699,433		$	—	$	—		$	699,433
	Derivative liability	$	—		$	—	$	(338,647	)	$	(338,647	)
Derivative liability assumptions	'
	Risk free interest rate	0 to 0.13 %
	Expected life	0 to 1 years
	Dividend Yield	0%
	Volatility	0% to 108%
Reconciliation of the derivative liability	'
	Value at December 31, 2013	$	359,407
	Change in value of derivative	$	(20,760	)
	Value at September 30, 2014	$	338,647

3_Notes_and_loans_payable_Tabl

3. Notes and loans payable (Tables)	9 Months Ended
	Sep. 30, 2014
Notes And Loans Payable Tables	'
Notes and loans payable	'
	At September 30, 2014 and December 31, 2013 notes and loans payable consist of:
			September 30,		December 31,
			2014		2013
	Convertible Promissory Note Payable to St. George Investment, secured by the Company’s assets, interest rate of 6.0% per annum, with payment due on or before March 10, 2015		259,530		259,530
	Secured Convertible Promissory Note to Tonaquint, Inc., 6% per annum; due on or before February 27, 2014		1,252,000		1,252,000
	(See Item 1. Legal Proceedings as described more fully)
			1,511,530		1,511,530
	Less: Unamortized Discount	-19,364			(70,195	)
		$	1,492,166	$	1,441,335

5_Discontinued_Operations_Tabl

5. Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2014
Discontinued Operations Tables	'
Discontinued Operations, summary of certain assets and liabilities and gain on sale of BioCell reported	'
	A summary of certain assets and liabilities disposed of or discharged directly or indirectly in connection with this transaction as of September 30, 2014 was as follows:
	Cash	$	37,432
	Accounts receivable		142,510
	Other current assets		104,388
	Prepaid expenses		275,866
	Total current assets		560,196
	Property and equipment, net of accumulated depreciation		520,744
	Customer contracts and relationships, net of amortization		1,019,147
	Other assets		24,041
	Goodwill		244,053
	Total assets	$	2,368,181
	Accounts payable	$	213,054
	Accrued expenses		1,082,542
	Deferred revenue		1,192,008
	Total liabilities	$	2,487,604
	The gain on sale of BioCells reported during the period was determined as follows:
	Receivable from sale of BioCells	$	705,000
	Unamortized discount on receivable		(215,991	)
	Receivable, net of discount		489,009
	Net assets		(119,423	)
	Non-controlling interest		188,018
	Comprehensive loss		(694,777	)
	Subtotal of disposal from sale of BioCells		(626,182	)
	Net gain on sale of BioCells	$	1,115,191

6_Commitments_and_Contingencie1

6. Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments And Contingencies Tables	'
Future minimum rental payments	'
		Rent
		to be paid
	2014	$	43,839
	2015		176,497
	2016		180,997
	2017		185,354
	2018		189,842
	Thereafter		144,962
	Total	$	921,490

8_Share_Based_Compensation_Tab

8. Share Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
Stock option activity	'
	The Company’s stock option activity was as follows:
			Stock				Weighted Average Exercise Price				Weighted Avg. Contractual
			Options								Remaining Life
	Outstanding, January 1, 2013			6,323,570				1.01				5.76
	Exercised			-				-				-
	Forfeited/Expired			627,740				-				-
	Outstanding, December 31, 2013			5,570,830				1.01				4.51
	Exercisable at December 31, 2013			5,570,830				1.01				4.51
	Forfeited/Expired			12,000				-				-
	Outstanding, June 30, 2014			5,558,830				1.01				4.01
	Exercisable at June 30, 2014			5,558,830				1.01
	Forfeited/Expired			462,055
	Outstanding, September 30, 2014			5,106,775				1.01				3.51
	Exercisable, September 30, 2014			5,106,775				1.01
Summary of significant ranges of outstanding stock options	'
	The following table summarizes significant ranges of outstanding stock options under the stock option plan at September 30, 2014:
	Range of				Number of				Weighted Average				Weighted Average		Number of		Weighted Average
	Exercise Prices				Options				Remaining				Exercise		Options		Exercise
									Contractual Life				Price		Exercisable		Price
									(years)
	$	0.33 — 20.00				5,070,751				3.53			$	0.83		5,070,751	$	0.72
	$	21.00 — 30.00				18,126				0.37				25		18,126		15.04
	$	31.00— 51.00				17,898				3.51				31.21		17,898		31.21
						5,106,775				3.51			$	1.01		5,106,775	$	1.01
Summary of the activity for unvested employee stock options	'
	A summary of the activity for unvested employee stock options as of September 30, 2014 and changes during the period presented below:
	Weighted Average Grant Date Fair Value per Share
			Stock				Weighted Avg.
			Options				Grant Date
							Fair Value per
							Share
	Nonvested at January 1, 2014			--				0.39
	Granted			--				--
	Vested			--				--
	Exercised			--				--
	Cancelled			--				--
	Pre-vested forfeitures			--				--
	Nonvested at September 30, 2014			--				0.39

9_Warrant_Agreements_Tables

9. Warrant Agreements (Tables)	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
Summarizes of the warrants outstanding and exercisable	'
	The following table summarizes the warrants outstanding and exercisable at September 30, 2014:
		WARRANTS OUTSTANDING		EXERCISE		MATURITY DATE
				PRICE
			1,392,354	$	0.01	3/10/16
	Total		1,392,354

11_Segment_Reporting_Tables

11. Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
Financial information by business segment	'
	The table below presents certain financial information by business segment for the nine months ended September 30, 2014:
		Cord		Biocordcell		Segment		Consolidation		Condensed
						Total		Eliminations		Consolidated
										Total
	Revenue fromExternal Customers	$	3,136,047	$	--	$	3,136,047	$	-	$	3,136,047
	Interest & Derivative Expense		303,159		--		303,159		-		303,159
	Depreciation and Amortization		402,252		--		402,252				402,252
	Segment Loss from continuing operations		-554,063		--		-554,063		-		-554,063
	Gain from discontinued operations				776,995		776,995				776,995
	Segment Assets	$	3,959,423	$	--	$		$	3,959,423	$	3,959,423
	The table below presents certain financial information by business segment for the three months ended September 30, 2014:
		Cord		Biocordcell		Segment		Consolidation		Condensed
						Total		Eliminations		Consolidated
										Total
	Revenue from External Customers	$	1,197,268	$	--	$	1,197,268	$	-	$	1,197,268
	Interest & Derivative Expense		518,508		--		518,508				518,508
	Depreciation and Amortization		133,692		--		133,692				133,692
	Segment Income from continuing operations		538,657		--		538,657		-		538,657
	Gain from discontinued operations				966,712		966,712				966,712
	Segment Assets	$	3,959,423	$	--	$	3,959,423	$		$	3,959,423
	The table below presents certain financial information by business segment for the nine months ended September 30, 2013:
		Cord		Biocordcell		Segment		Consolidation		Condensed
						Total		Eliminations		Consolidated
										Total
	Revenue from External Customers	$	2,842,703		1,584,520		4,427,223				4,427,223
	Interest & Derivative Expense		1,045,512		91,565		1,137,077				1,137,077
	Depreciation and Amortization		540,630		37,174		577,804				577,804
	Segment Loss from continuing operations		-1,128,761		-558,208		-1,686,969				(1,686,969	)
	Segment Assets	$	4,655,965		1,892,027		6,547,992		-138,383		6,409,609
	The table below presents certain financial information by business segment for the three months ended September 30, 2013:
		Cord		Biocordcell		Segment		Consolidation		Condensed
						Total		Eliminations		Consolidated
										Total
	Revenue from External Customers	$	959,239		527,763		1,487,002				1,487,002
	Interest & Derivative Expense		289,824		47,901		337,725				337,725
	Depreciation and Amortization		180,024		11,976		192,000				192,000
	Segment Loss from continuing operations		-315,932		-275,802		-591,734				-591,734
	Segment Assets	$	4,655,965		1,892,027		6,547,992		-138,383		6,409,609

2_Summary_of_Significant_Accou3

2. Summary of Significant Accounting Policies (Details) (USD $)	Sep. 30, 2014
Fair Value, Measurements, Recurring [Member]	'
Summary of assets and liabilities measured at fair value on a recurring basis	'
Cash and cash equivalents	$699,433
Derivative liability	-338,647
Fair Value, Measurements, Recurring [Member], Level 1 [Member]	'
Summary of assets and liabilities measured at fair value on a recurring basis	'
Cash and cash equivalents	699,433
Derivative liability	'
Fair Value, Measurements, Recurring [Member], Level 2 [Member]	'
Summary of assets and liabilities measured at fair value on a recurring basis	'
Cash and cash equivalents	'
Derivative liability	'
Fair Value, Measurements, Recurring [Member], Level 3 [Member]	'
Summary of assets and liabilities measured at fair value on a recurring basis	'
Cash and cash equivalents	'
Derivative liability	($338,647)

2_Summary_of_Significant_Accou4

2. Summary of Significant Accounting Policies (Details 1)	9 Months Ended
	Sep. 30, 2014
Dividend Yield	0.00%
Minimum [Member]	'
Risk free interest rate	0.00%
Expected life	'0 years
Volatility	0.00%
Maximum [Member]	'
Risk free interest rate	0.13%
Expected life	'1 year
Volatility	108.00%

2_Summary_of_Significant_Accou5

2. Summary of Significant Accounting Policies (Details 2) (USD $)	9 Months Ended
	Sep. 30, 2014
Notes to Financial Statements	'
Value at Beginning	$359,407
Change in value of derivative	-20,760
Value at Ending	$338,647

2_Summary_of_Significant_Accou6

2. Summary of Significant Accounting Policies (Details Narrative) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Notes to Financial Statements	'	'	'
Accumulated deficit	($53,462,504)	'	($53,685,436)
Notes and loans payable	1,511,530	'	1,511,530
Cash flow from operations	956,590	333,034	'
Impairment loss	'	'	$204,062

3_Notes_and_Loans_Payable_Deta

3. Notes and Loans Payable (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Notes and loans payable	$1,511,530	$1,511,530
Less: Unamortized Discount	19,364	-70,195
Notes and loans payable, Net	1,492,166	1,441,335
Convertible Promissory Note Payable To St George Investment [Member]	'	'
Notes and loans payable	259,530	259,530
Secured Convertible Promissory Note To Tonaquint [Member]	'	'
Notes and loans payable	$1,252,000	$1,252,000

4_Loans_Receivables_Details

4. Loans Receivables (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Loans Receivables Details	'	'
Receivable	$489,009	'
Unamortized Discount	$215,991	'

5_Discontinued_Operations_Deta

5. Discontinued Operations (Details) (USD $)	Sep. 30, 2014
Discontinued Operations Details	'
Cash	$37,432
Accounts receivable	142,510
Other current assets	104,388
Prepaid expenses	275,866
Total current assets	560,196
Property and equipment, net of accumulated depreciation	520,744
Customer contracts and relationships, net of amortization	1,019,147
Other assets	24,041
Goodwill	244,053
Total assets	2,368,181
Accounts payable	213,054
Accrued expenses	1,082,542
Deferred revenue	1,192,008
Total liabilities	$2,487,604

5_Discontinued_Operations_Deta1

5. Discontinued Operations (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2014
Discontinued Operations Details 1	'
Receivable from sale of BioCells	$705,000
Unamortized discount on receivable	-215,991
Receivable, net of discount	489,009
Net assets	-119,423
Non-controlling interest	188,018
Comprehensive loss	-694,777
Subtotal of disposal from sale of BioCells	-626,182
Net gain on sale of BioCells	$1,115,191

6_Commitments_and_Contingencie2

6. Commitments and Contingencies (Details) (USD $)	Sep. 30, 2014
Commitments And Contingencies Tables	'
2014	$43,839
2015	176,497
2016	180,997
2017	185,354
2018	189,842
Thereafter	144,962
Total	$921,490

6_Commitments_and_Contingencie3

6. Commitments and Contingencies (Details Narrative) (USD $)	Sep. 30, 2014
St. George Investments	'
Principal balance due	$259,530
Accrued expenses	43,279
Tonaquint, Inc	'
Principal balance due	1,252,000
Accrued expenses	553,771
Patent License Agreement	'
Accrued expenses	120,000
Accounts payable	$226,000

8_Share_Based_Compensation_Det

8. Share Based Compensation (Details) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
Share Based Compensation Details	'	'	'
Beginning Balance, shares	5,558,830	5,570,830	6,323,570
Begining Balance Exercisable, shares	5,558,830	5,570,830	'
Forfeited/Expired, shares	462,055	12,000	627,740
Ending Balance, shares	5,106,775	5,558,830	5,570,830
Ending Balance Exercisable, shares	5,106,775	5,558,830	5,570,830
Beginning Balance, weighted average exercise price	$1.01	$1.01	$1.01
Begining Balance Exercisable, weighted average exercise price	$1.01	$1.01	'
Ending Balance, weighted average exercise price	$1.01	$1.01	$1.01
Ending Balance Exercisable, weighted average exercise price	$1.01	$1.01	$1.01
Beginning Balance, Weighted Avg. Contractual Remaining Life (in years)	'4 years 4 days	'4 years 6 months 4 days	'5 years 9 months 4 days
Begining Balance Exercisable, Weighted Avg. Contractual Remaining Life (in years)	'	'	'4 years 6 months 4 days
Forfeited/Expired, Weighted Avg. Contractual Remaining Life (in years)	'3 years 6 months 4 days	'4 years 4 days	'4 years 6 months 4 days

8_Share_Based_Compensation_Det1

8. Share Based Compensation (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of Options	5,106,775	5,558,830	5,570,830	6,323,570
Weighted Average Remaining Contractual Life (years)	'3 years 6 months 4 days	'	'	'
Weighted Average Exercise Price	$1.01	$1.01	$1.01	$1.01
Number of Options Exercisable	5,106,775	5,558,830	5,570,830	'
Weighted Average Exercise Price	$1.01	$1.01	$1.01	'
RangeOneMember	'	'	'	'
Range of Exercise Prices	'0.33 B 20.00	'	'	'
Number of Options	5,070,751	'	'	'
Weighted Average Remaining Contractual Life (years)	'3 years 6 months 11 days	'	'	'
Weighted Average Exercise Price	$0.83	'	'	'
Number of Options Exercisable	5,070,751	'	'	'
Weighted Average Exercise Price	$0.72	'	'	'
RangeTwoMember	'	'	'	'
Range of Exercise Prices	'21.00 B 30.00	'	'	'
Number of Options	18,126	'	'	'
Weighted Average Remaining Contractual Life (years)	'4 months 13 days	'	'	'
Weighted Average Exercise Price	$25	'	'	'
Number of Options Exercisable	18,126	'	'	'
Weighted Average Exercise Price	$15.04	'	'	'
RangeThreeMember	'	'	'	'
Range of Exercise Prices	'31.00B 51.00	'	'	'
Number of Options	17,898	'	'	'
Weighted Average Remaining Contractual Life (years)	'3 years 6 months 4 days	'	'	'
Weighted Average Exercise Price	$31.21	'	'	'
Number of Options Exercisable	17,898	'	'	'
Weighted Average Exercise Price	$31.21	'	'	'

8_Share_Based_Compensation_Det2

8. Share Based Compensation (Details 2) (USD $)	9 Months Ended
	Sep. 30, 2014
Share Based Compensation Details 2	'
Nonvested at January 1, 2014	'
Granted	'
Vested	'
Exercised	'
Cancelled	'
Pre-vested forfeitures	'
Nonvested at January 1, 2014	$0.39
Granted	'
Vested	'
Exercised	'
Cancelled	'
Pre-vested forfeitures	'
Nonvested at June 30, 2014	$0.39

9_Warrant_Agreements_Details

9. Warrant Agreements (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Warrant Agreements Details	'
WARRANTS OUTSTANDING	1,392,354
EXERCISE PRICE	$0.01
MATURITY DATE	3-Oct-16

10_Stockholders_Equity_Details

10. Stockholders Equity (Details Narrative) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Stockholders Equity Details Narrative	'	'
Preferred stock authorized	5,000,000	5,000,000
Preferred stock, par value	$0.00	$0.00
Number of Shares Issued to Retire	'	513,765,592
Convertible debt	'	$1,823,206
Common Stock outstanding	890,000,000	890,000,000
Treasury stock	20,000	20,000

11_Segment_Reporting_Details

11. Segment Reporting (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue from external customer	$1,197,268	$1,487,002	$3,136,047	$4,427,223
Interest & Derivative Expense	518,508	337,725	303,159	1,137,077
Depreciation and Amortization	133,692	192,000	402,252	577,804
Segment Income (Loss) from continuing operations	538,657	-591,734	-554,063	-1,686,969
Gain from discontinued operations	966,712	'	776,995	'
Segment Assets	3,959,423	6,409,609	3,959,423	6,409,609
CordMember	'	'	'	'
Revenue from external customer	1,197,268	959,239	3,136,047	2,842,703
Interest & Derivative Expense	518,508	289,824	303,159	1,045,512
Depreciation and Amortization	133,692	180,024	402,252	540,630
Segment Income (Loss) from continuing operations	538,657	-315,932	-554,063	-1,128,761
Segment Assets	3,959,423	4,655,965	3,959,423	4,655,965
BiocordcellMember	'	'	'	'
Revenue from external customer	'	527,763	'	1,584,520
Interest & Derivative Expense	'	47,901	'	91,565
Depreciation and Amortization	'	11,976	'	37,174
Segment Income (Loss) from continuing operations	'	-275,802	'	-558,208
Gain from discontinued operations	966,712	'	776,995	'
Segment Assets	'	1,892,027	'	1,892,027
SegmentTotalMember	'	'	'	'
Revenue from external customer	1,197,268	1,487,002	3,136,047	4,427,223
Interest & Derivative Expense	518,508	337,725	303,159	1,137,077
Depreciation and Amortization	133,692	192,000	402,252	577,804
Segment Income (Loss) from continuing operations	538,657	-591,734	-554,063	-1,686,969
Gain from discontinued operations	966,712	'	776,995	'
Segment Assets	3,959,423	6,547,992	3,959,423	6,547,992
Consolidation Eliminations	'	'	'	'
Revenue from external customer	'	'	'	'
Interest & Derivative Expense	'	'	'	'
Segment Income (Loss) from continuing operations	'	'	'	'
Segment Assets	'	($138,383)	$3,959,423	($138,383)